About Pricing FAQs Blog

Loading clinical trials...

Clareo Health Find Clinical Trials →

© 2026 Clareo Health. All rights reserved.

Schizophrenia Clinical Trials in San Antonio | 65 Studies | Clareo Health

Clinical Trials SchizophreniaSan Antonio

Schizophrenia Clinical Trials in San Antonio

Find 65 clinical trials for schizophrenia near San Antonio, Texas. Connect with research centers in your area.

All Schizophrenia trials nationwide All trials in San Antonio

Filters

Sort by

Status

Recruiting(Enrolling)

Not yet recruiting

Active, not recruiting

Enrolling by invitation(Enrolling)

Completed

Terminated

Phase

Early Phase 1

Phase 1

Phase 1/Phase 2

Phase 2

Phase 2/Phase 3

Phase 3

Phase 4

Not Applicable

Eligibility

Accepts healthy volunteers

Showing 41-60 of 65 trials

COMPLETEDNA< 1 mile

Cognitive Adaptive Training for Improving Medication Adherence, Symptoms, and Function in People With Schizophrenia

NCT00455663

This study will compare the effectiveness of three treatments in improving medication adherence, symptoms, and function in people with schizophrenia.

The University of Texas Health Science Center at San Antonio105 participantsStarted Nov 2000

San Antonio, Texas, United States

COMPLETEDPHASE3< 1 mile

Effects of Aripiprazole in Overweight Patients Treated With Olanzapine for Schizophrenia or Schizoaffective Disorder

NCT00095524

The primary purpose of this study is to compare the affects of aripiprazole and olanzapine on weight change.

Body Weight ChangeSchizophreniaSchizoaffective Disorder+1 more

Otsuka Pharmaceutical Development & Commercialization, Inc.300 participantsStarted Mar 2004

Little Rock, Arkansas, United States • Anaheim, California, United States • Cerritos, California, United States +29 more locations

Schizophrenia Trials in Other Cities

New York Los Angeles Chicago Houston Phoenix Philadelphia

Data from ClinicalTrials.govTerms

COMPLETEDNA< 1 mile

The Consta Club: A Demonstration Project for Setting up a Consta Club in a Community Mental Health Center

NCT00845572

This study will establish a bi-weekly Consta Club. Participants will begin taking Risperdal Consta after being recommended by their treating physician. As a part of the Consta Club attendees will receive their injection of Risperdal Consta and be educated about important mental health issues. Interviews with study participants will be completed every three months to determine the effectiveness of the change to Risperdal Consta and the bi-weekly group. The overall hypothesis is that the individuals in Consta Club will have a decrease in walk-in visits, emergency procedures and hospitalizations. It is also believed that individuals in Consta Club will have fewer symptoms and better levels of functioning.

SchizophreniaSchizoaffective

The University of Texas Health Science Center at San Antonio30 participantsStarted Jan 2007

San Antonio, Texas, United States

COMPLETEDPHASE274 miles

Efficacy and Safety Study for Cognitive Deficits in Adult Subjects With Schizophrenia

NCT01077700

This is an efficacy and safety study evaluating an experimental treatment for cognitive deficits in adults with schizophrenia.

Cognitive Deficits in Schizophrenia

AbbVie (prior sponsor, Abbott)214 participantsStarted Mar 2010

Anaheim, California, United States • Garden Grove, California, United States • National City, California, United States +21 more locations

COMPLETEDPHASE374 miles

A Study of RO4917838 (Bitopertin) in Patients With Sub-optimally Controlled Symptoms of Schizophrenia (WN25305)

NCT01235559

This randomized, multi-center double-blind, parallel-group, placebo-controlled study will evaluate the efficacy and safety of RO4917838 (bitopertin) in patients with sub-optimally controlled symptoms of schizophrenia. Patients, on stable treatment with antipsychotics, will be randomized to receive daily oral doses of RO4917838 or matching placebo for 52 weeks, followed by an optional treatment extension for up to 3 years.

Hoffmann-La Roche604 participantsStarted Dec 2010

Costa Mesa, California, United States • Escondido, California, United States • Granada Hills, California, United States +87 more locations

COMPLETEDPHASE374 miles

Lurasidone HCl: A Phase 3 Study of Patients With Acute Schizophrenia

NCT00549718

Lurasidone HCl is a compound being developed for the treatment of schizophrenia. This clinical study is designed to test the hypothesis that lurasidone is more efficacious than placebo. The study will also evaluate the safety and tolerability of lurasidone as compared to placebo.

Sumitomo Pharma America, Inc.489 participantsStarted Oct 2007

Little Rock, Arkansas, United States • Cerritos, California, United States • Costa Mesa, California, United States +45 more locations

COMPLETEDPHASE374 miles

A Study Evaluating Lurasidone for The Treatment of Schizophrenia or Schizoaffective Disorder in Subjects Switched From Other Antipsychotic Agents

NCT01143077

Lurasidone (lurasidone HCl) is a novel psychotropic agent that is being developed as a potential new antipsychotic treatment for patients with schizophrenia. Switching between antipsychotic medications is common in the treatment of schizophrenia. The current study is designed to evaluate the effectiveness, safety, and tolerability of switching clinically stable, but symptomatic outpatients with schizophrenia or schizoaffective disorder from their preswitch antipsychotic medication to lurasidone, over a period of 6 weeks.

SchizophreniaSchizoaffective Disorder

Sumitomo Pharma America, Inc.244 participantsStarted Jun 2010

Little Rock, Arkansas, United States • Escondido, California, United States • Garden Grove, California, United States +24 more locations

COMPLETEDPHASE274 miles

Effect Of Talnetant Versus Risperidone Versus Placebo On Psychotic Symptoms In Schizophrenic Patients

NCT00300963

The purpose of this study is to test the safety and effectiveness of talnetant vs. risperidone vs. placebo in reducing positive and negative symptoms in acutely psychotic schizophrenia patients.

GlaxoSmithKline275 participantsStarted Dec 2004

Little Rock, Arkansas, United States • Anaheim, California, United States • Cerritos, California, United States +17 more locations

TERMINATEDPHASE2/PHASE374 miles

A Long-Term, Open-Label, Study on Schizophrenia

NCT01129674

The primary purpose of the study is to help answer the following research questions: How LY 2140023 can be tolerated by patients with Schizophrenia compared to standard of care treatment in 52 weeks time period. Whether LY 2140023 can help patients with Schizophrenia.

Eli Lilly and Company1,210 participantsStarted Jun 2010

Little Rock, Arkansas, United States • Escondido, California, United States • Garden Grove, California, United States +78 more locations

COMPLETEDPHASE274 miles

Study to Evaluate the Efficacy and Safety of Armodafinil as Adjunctive Therapy in Adults With Schizophrenia

NCT00772005

The primary objective of the study is to evaluate whether armodafinil treatment is more effective than placebo as adjunctive therapy to antipsychotic medication in alleviating the negative symptoms of schizophrenia

Cephalon287 participantsStarted Sep 2008

Little Rock, Arkansas, United States • Anaheim, California, United States • Escondido, California, United States +36 more locations

COMPLETED167 miles

CSP #572 - Genetics of Functional Disability in Schizophrenia and Bipolar Illness

NCT01149551

The purpose of this study is to detect genetic associations for the development of schizophrenia (SZ) and bipolar illness (BP) by comparing Veterans with these diseases to "psychiatrically healthy" Veterans from Veterans Health Administration medical centers. In addition, the genetic basis for functional capacity and disability in Veterans affected with SZ and BP will be assessed, as will genetic predictors of suicidality and tardive dyskinesia. Finally, we will also establish a repository which allows for future genomic studies related to SZ, BP, and related disorders or sequelae.

SchizophreniaBipolar Disorder

US Department of Veterans Affairs9,356 participantsStarted Feb 2011

Birmingham, Alabama, United States • Tuscaloosa, Alabama, United States • No. Little Rock, Arkansas, United States +22 more locations

COMPLETEDPHASE3183 miles

A Study of RO4917838 in Patients With Sub-optimally Controlled Symptoms of Schizophrenia (NN25307)

NCT01235520

This randomized, multi-center, double-blind, parallel-group, placebo-controlled study will evaluate the efficacy and safety of RO4917838 in patients with sub-optimally controlled symptoms of schizophrenia. Patients, on stable treatment with antipsychotics, will be randomized to receive daily oral doses of RO4917838 or matching placebo for 52 weeks, followed by an optional treatment extension for up to 3 years.

Hoffmann-La Roche595 participantsStarted Jan 2011

Little Rock, Arkansas, United States • Little Rock, Arkansas, United States • Buena Park, California, United States +118 more locations

COMPLETEDPHASE1190 miles

Effects of Cariprazine on Cardiac Repolarization in Patients With Schizophrenia

NCT01376076

This study will evaluate the effects of sequential multiple dose regimens of cariprazine on cardiac repolarization in patients with schizophrenia.

Forest Laboratories129 participantsStarted Jun 2011

Glendale, California, United States • Long Beach, California, United States • Willingboro, New Jersey, United States +1 more locations

COMPLETEDPHASE3322 miles

Open-label Study of Flexible-dose Paliperidone ER (Extended Release) to Treat Adolescent Schizophrenia.

NCT00488319

The purpose of this open-label study is to evaluate the long-term (6-month) safety and tolerability of extended-release paliperidone, an atypical antipsychotic, given in flexible dosages to adolescents with schizophrenia.

SchizophreniaSchizophrenic DisordersPsychotic Disorders+1 more

Janssen Research & Development, LLC400 participantsStarted Jun 2007

Cerritos, California, United States • San Diego, California, United States • Santa Ana, California, United States +50 more locations

COMPLETEDNA616 miles

Improving Care and Reducing Cost Study

NCT02364544

The goal of the Improving Care and Reducing Cost (ICRC) Program, is to improve disease management and the overall process of care in treating the chronic illness schizophrenia in order to reduce ER visits and hospital days while providing better care, better health and increased patient satisfaction. This will be done by fostering innovation in the use of technology and by training and deploying a new cadre of personnel in the behavioral health field: Mental Health/Health Technology (MH/HT) Case Managers.

SchizophreniaSchizoaffective DisorderPsychosis NOS

Northwell Health461 participantsStarted Apr 2013

Fort Lauderdale, Florida, United States • Lawrenceburg, Indiana, United States • Grand Rapids, Michigan, United States +5 more locations

COMPLETEDPHASE4798 miles

A Study to Evaluate the Safety and the Effects of Risperidone Compared With Other Atypical Antipsychotic Drugs on the Growth and Sexual Maturation in Children

NCT01050582

The purpose of this study is to evaluate the effects of risperidone compared with other atypical antipsychotic drugs on the physical maturity, growth and development of children, and the risk of prolactin-related adverse events (side effects) associated to these drugs.

SchizophreniaBipolar DisorderAutistic Disorder+1 more

Johnson & Johnson Pharmaceutical Research & Development, L.L.C.244 participantsStarted Oct 2009

San Francisco, California, United States • Aurora, Colorado, United States • Altamonte Springs, Florida, United States +25 more locations

COMPLETEDPHASE3881 miles

Efficacy & Safety Study of Oral Aripiprazole in Adolescents With Schizophrenia

NCT01149655

This will be a randomized, double-blind, placebo-controlled study consisting of a screening period, a conversion phase (Phase 1), a stabilization phase (Phase 2), and a double-blind maintenance treatment phase (Phase 3), and a follow up period. Subjects may be either outpatients or inpatients between screening and through the time they reach stabilization at the end of Phase 2; hospitalization is not a study requirement. However, eligible subjects must be outpatients at the beginning of Phase 3. Subjects will be assessed weekly during Phase 1, weekly for the first 4 weeks of Phase 2 and 3, and biweekly for the remaining weeks during each of Phases 2 and 3. Subjects will be encouraged to call the investigators with any exacerbation of psychotic symptoms and/or any tolerability issues. The investigator will also have the option to phone the subjects and their guardian(s) at any time to ensure clinical stability. A data monitoring committee (DMC) will provide oversight for safety monitoring and reviewing the interim analysis. One interim analysis is planned after 75% of the total expected number of impending relapse events (28 events) are achieved and will be conducted by an independent data analysis center. The DMC will make a recommendation about stopping or continuing the study based on safety and efficacy reviews. The results of the interim analysis and individual subject data will remain blinded to the sponsor during the course of the study until the DMC determines that the study will conclude based on the results of the interim analysis, or the study is completed after 37 endpoint events.

Otsuka Pharmaceutical Development & Commercialization, Inc.252 participantsStarted Jul 2011

Downy, California, United States • Glendale, California, United States • Miami, Florida, United States +49 more locations

TERMINATEDPHASE2881 miles

Olanzapine Given in Combination With Zonisamide SR to Prevent Weight Gain in Schizophrenic Subjects

NCT00734435

The purpose of this study is to determine if zonisamide SR will prevent weight gain in schizophrenic subjects who take olanzapine (Zyprexa)

SchizophreniaSchizoaffective DisorderSchizophreniform Disorder

Orexigen Therapeutics, Inc26 participantsStarted Sep 2008

National City, California, United States • Orange, California, United States • San Diego, California, United States +6 more locations

TERMINATEDPHASE21035 miles

A Study to Assess the Clinical Utility of Antipsychotic Medication Levels in Plasma as Determined by Liquid Chromatography-Tandem Mass Spectrometry

NCT02462473

The purpose of this study is to determine the number of Medication Treatment Modifications (MTMs) made by the clinician at every visit when antipsychotic medication plasma levels (AMPL) results are available compared to when AMPL results are not available.

SchizophreniaSchizoaffective Disorder

Janssen Research & Development, LLC9 participantsStarted May 2015

Torrance, California, United States • Kissimmee, Florida, United States • Conshohocken, Pennsylvania, United States

COMPLETED1238 miles

An Non-Interventional Study of Patients With Persistent Symptoms of Schizophrenia

NCT01634542

This multicenter, prospective, non-interventional study will evaluate the prevalence and characteristics of patients with persistent symptoms of schizophrenia and the course of their illness over 24 months.

Hoffmann-La Roche1,433 participantsStarted Feb 2011

Buenos Aires, Argentina • Caba, Argentina • La Plata, Argentina +145 more locations

PreviousPage 3 of 4Next

Other Conditions in San Antonio

Breast Cancer Lung Cancer Prostate Cancer Colorectal Cancer Melanoma Leukemia